Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Mar;115(3):739-46.
doi: 10.1172/JCI23373.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Daniel E Speiser  1 , Danielle Liénard, Nathalie Rufer, Verena Rubio-Godoy, Donata Rimoldi, Ferdy Lejeune, Arthur M Krieg, Jean-Charles Cerottini, Pedro Romero
Affiliations
Clinical Trial

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Daniel E Speiser et al. J Clin Invest. 2005 Mar.

Abstract

The induction of potent CD8+ T cell responses by vaccines to fight microbes or tumors remains a major challenge, as many candidates for human vaccines have proved to be poorly immunogenic. Deoxycytidyl-deoxyguanosin oligodeoxynucleotides (CpG ODNs) trigger Toll-like receptor 9, resulting in dendritic cell maturation that can enhance immunogenicity of peptide-based vaccines in mice. We tested whether a synthetic ODN, CpG 7909, could improve human tumor antigen-specific CD8+ T cell responses. Eight HLA-A2+ melanoma patients received 4 monthly vaccinations of low-dose CpG 7909 mixed with melanoma antigen A (Melan-A; identical to MART-1) analog peptide and incomplete Freund's adjuvant. All patients exhibited rapid and strong antigen-specific T cell responses: the frequency of Melan-A-specific T cells reached over 3% of circulating CD8+ T cells. This was one order of magnitude higher than the frequency seen in 8 control patients treated similarly but without CpG and 1-3 orders of magnitude higher than that seen in previous studies with synthetic vaccines. The enhanced T cell populations consisted primarily of effector memory cells, which in part secreted IFN- and expressed granzyme B and perforin ex vivo. In vitro, T cell clones recognized and killed melanoma cells in an antigen-specific manner. Thus, CpG 7909 is an efficient vaccine adjuvant that promotes strong antigen-specific CD8+ T cell responses in humans.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rapid in vivo responses of Melan-A–specific T cells to vaccination (vacc) with low doses of CpG 7909, Melan-A peptide, and IFA. PBMCs were collected before, as well as 7–10 days after, vaccinations 2 and 4, and they were analyzed ex vivo by flow cytometry. (A) Dot plots from PBMCs of patient LAU 627, with percentage of Melan-A–specific cells among CD8+ T cells. (B) After 2 and 4 vaccinations, 6/8 and 8/8 patients, respectively, had significantly increased percentages (i.e., greater than 2-fold) of Melan-A–specific T cells. (C) A control group of 8 patients was similarly treated with Melan-A peptide and IFA but without CpG (23). After 2 vaccinations, none of the patients had more than 2-fold increased percentages. After 4 vaccinations, 4/8 patients had more than 2-fold increased frequencies, but percentages of Melan-A–specific T cells remained significantly (P < 0.01) lower as compared to those of CpG-vaccinated patients. (D) Fold increase of Melan-A–specific T cells before or after 4 vaccinations in patients vaccinated with or without CpG. Horizontal lines indicate mean values.
Figure 2
Figure 2
T cell responses to CpG vaccination (arrows) in patients that previously did not respond to vaccination with Melan-A peptide and immunological adjuvants MPL and QS21 (vertical lines). Percentages of multimer+ T cells were determined ex vivo in PBMCs collected over an observation period of 4 to 5 years. (A) Patient LAU 321; (B) Patient LAU 371.
Figure 3
Figure 3
Short-term kinetics of Melan-A–specific T cells from 2 representative patients with maximal (max.) responses on day 7 (patient LAU 818) and on day 10 (patient LAU 627) after recall vaccination with CpG 7909, Melan-A peptide, and IFA. PBMCs were collected immediately before, as well as 7, 10, and 14 days after, recall vaccination. Percentages of multimer+ T cells were determined ex vivo and calculated in percentages of maximally reached values (100%) per patient.
Figure 4
Figure 4
Expression of effector mediators by vaccine-activated Melan-A–specific T cells. Multiparameter cytometric analysis and sorting was performed with A2/Melan-A multimers and antibodies specific for CD8, CD45RA, and CCR7. (A) Expression of CD45RA and CCR7 is shown for A2/Melan-A multimer+ CD8+ gated cells. (B) RT-PCR gene expression analysis was performed (33) using primers specific for CD3, granzyme B, perforin, IFN-γ, TNF-α, and CD94, on sorted A2/Melan-A multimer+ T cells which were RA+CCR7+ (naive cells) or RA–CCR7+ effector memory cells. Each band represents the RT-PCR product from RNA isolated from sorted 5-cell aliquots. Data in A and B (representative of 8 and 2 patients analyzed, respectively) are from PBMCs collected from patient LAU 371 before and after 2 and 4 vaccinations. +, positive control; –, negative control; N, naive T cells; EM, effector memory T cells.
Figure 5
Figure 5
T cell receptor fine-specificity and tumor cell recognition. (A) PBMCs from patient LAU 371 were tested ex vivo in IFN-γ Elispot assays before and after vaccination with HIV, tyrosinase, and Melan-A natural and analog peptides. (B) Melan-A–specific T cells were sorted by flow cytometry and cloned, and cytotoxicity was tested against T2 cells in the presence of the following titrated HLA-A2 binding peptides: Melan-A analog (squares), Melan-A natural decamer (circles), Melan-A natural nonamer (triangles), and influenza matrix protein GILGFVFTL (diamonds). (C) Cytotoxicity against HLA-A2+ melanoma cell lines Me 275 (Melan-A+; filled symbols) and NA8 (Melan-A–; open symbols) in the presence (squares) or absence (circles) of synthetic Melan-A analog peptide. Data shown were generated with clone 6 derived from patient LAU 371 and are representative for 12 of 22 clones generated from patients LAU 371 and LAU 444.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Janeway CA., Jr Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989;54:1–13. - PubMed
    1. Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell. 1994;76:323–332. - PubMed
    1. Medzhitov R, Janeway CA., Jr Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 1997;9:4–9. - PubMed
    1. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001;2:675–680. - PubMed
    1. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001;194:863–869. - PMC - PubMed

Publication types

MeSH terms